Sung Hee Lim
Overview
Explore the profile of Sung Hee Lim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
74
Citations
838
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shin M, Choi D, Jung J, Kim D, Lim S, Kim S, et al.
Cancer Res Treat
. 2025 Feb;
PMID: 39999774
Purpose: The epidermal growth factor receptor (EGFR) is a therapeutic target with confirmed clinical efficacy for several cancer types. We aimed to identify EGFR aberrations and their associations with other...
2.
Kim I, Kang S, Choi W, Seo A, Eom B, Kang B, et al.
J Gastric Cancer
. 2025 Jan;
25(1):5-114.
PMID: 39822170
Gastric cancer is one of the most common cancers in both Korea and worldwide. Since 2004, the Korean Practice Guidelines for Gastric Cancer have been regularly updated, with the 4th...
3.
Kim R, Park J, Kwon M, An M, Hong J, Park J, et al.
Oncol Res
. 2024 Dec;
33(1):57-65.
PMID: 39735665
Background: Immune checkpoint inhibitors (ICIs) are effective in a subset of patients with metastatic solid tumors. However, the patients who would benefit most from ICIs in biliary tract cancer (BTC)...
4.
Shin J, Lim S, Lee J, Lim H, Park Y, Kim S
Front Oncol
. 2024 Oct;
14:1450732.
PMID: 39403341
Introduction: Both regimens of TAS-102 (trifluridine/tipiracil) with and without bevacizumab are considered standard options for salvage treatment in patients with refractory metastatic colorectal cancer. Materials And Methods: This analysis included...
5.
The Impact of Pembrolizumab as a Salvage Therapy Based on HER2 Expression in Advanced Gastric Cancer
Lim S, Kim M, Lee J, Lim H, Kang W, Kim S
Cancers (Basel)
. 2024 Sep;
16(17).
PMID: 39272827
Immune checkpoint inhibitors (ICIs) are used as salvage treatments for advanced gastric cancer (AGC) regardless of HER2 status. This study assessed the efficacy of ICIs based on HER2 expression in...
6.
Kang S, Lim S, Kim M, Lee J, Park Y, Lim H, et al.
World J Gastrointest Oncol
. 2024 Aug;
16(8):3521-3528.
PMID: 39171162
Background: Bevacizumab, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody, inhibits angiogenesis and reduces tumor growth. Serum VEGF-C, lactate dehydrogenase, and inflammatory markers have been reported as predictive markers related...
7.
Lim S, Lee S, Hong J, Lee J, Kim S
Transl Cancer Res
. 2024 Aug;
13(7):3695-3703.
PMID: 39145064
Background: In v-raf murine sarcoma viral oncogene homolog B1 (BRAF)-mutant colorectal cancer (CRC), encorafenib-cetuximab has been established as standard second-line therapy, but not all patients respond and the duration of...
8.
Choi D, Jang H, Lim S, Kim S, Hong J, Park S, et al.
Pathol Res Pract
. 2024 Aug;
261:155473.
PMID: 39106591
Background: The Kirsten rat sarcoma virus (KRAS) is a prominent proto-oncogene. Several treatments for KRAS mutations have been developed. However, KRAS amplification, a KRAS alteration, is poorly understood, and there...
9.
Lim S, Saluja A, Vickers S, Hong J, Kim S, Lavania S, et al.
Cancer Lett
. 2024 Jun;
597():217041.
PMID: 38866072
Minnelide is a water-soluble disodium salt variant of triptolide, an HSP70 inhibitor that can prevent tumor progression and induce apoptosis. Maximum tolerated dose (MTD), safety, and antitumor activity of Minnelide...
10.
Lim S, Lee K, Kim J, Im H, Kim I, Han H, et al.
BMC Cancer
. 2024 Feb;
24(1):252.
PMID: 38395832
Background: Immune checkpoint inhibitor (ICI) or irinotecan-based chemotherapy is frequently used after failure of second-line paclitaxel plus ramucirumab treatment for patients with locally advanced unresectable or metastatic advanced gastric cancer...